Emily Minkow, MBA

Managing Director, Venture

Emily Minkow is a Managing Director with the Venture team at RA Capital Management. Emily’s primary responsibility is to lead venture-stage investments. Prior to RA Capital, Emily spent three years as a Venture Partner at Raven, RA Capital’s incubator, where she focused on creating and leading new biotech companies. Emily served as Interim CEO of Stylus Medicine, a stealth-stage genome engineering company, and as Consulting Chief Business Officer of Aliada Therapeutics through its acquisition by AbbVie. Prior to RA, Emily was Chief Business Officer of Prevail Therapeutics, a gene therapy company focused on genetic forms of neurodegenerative disease, from the company’s inception through its IPO and its acquisition by Eli Lilly in 2021. Previously, Emily spent much of her career at Celgene Corporation in positions of increasing responsibility in business development, in global marketing for the launch of Otezla for psoriasis and psoriatic arthritis, and as Principal to the Chairman and CEO. Emily started her career in strategy consulting at Frankel Group. Emily holds a BA from Princeton University and an MBA from Harvard Business School.